Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Invasive Ductal and Invasive Lobular Breast Carcinoma Clear all
Active, not recruiting Not applicable Interventional

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

NCT01644669
View directory record Official record
Conditions
Invasive Ductal Carcinoma, Ductal Carcinoma in Situ
Interventions
Intra-operative Radiation Therapy - IORT
Radiation
Lead sponsor
Xoft, Inc.
Industry
Eligibility
40 Years and older · Female only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 7, 2026, 9:53 PM EDT
Terminated Phase 4 Interventional

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

NCT05183828
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma of No Special Type
Interventions
Biospecimen Collection, Letrozole, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 7, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

NCT01849250
View directory record Official record
Conditions
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ, Paget Disease of the Breast, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Docosahexaenoic Acid, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Oct 7, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study

NCT05545150
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Bilateral Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8
Interventions
Intraoperative Imaging, Lumpectomy
Procedure · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Lexington, Kentucky • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 7, 2026, 9:53 PM EDT
Withdrawn Not applicable Interventional

Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT)

NCT01960803
View directory record Official record
Conditions
Invasive Ductal Breast Cancer, Carcinoma Breast Stage I
Interventions
Intraoperative Electron Radiotherapy
Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 95 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 7, 2026, 9:53 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

NCT04341129
View directory record Official record
Conditions
Breast Neoplasms, Breast Diseases, Breast Fibroadenoma, Breast Cancer
Interventions
Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 7, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer

NCT03345420
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
Hypofractionated Radiation Therapy
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 7, 2026, 9:53 PM EDT
Terminated Phase 1 Interventional Results available

Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

NCT02876640
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Early Stage Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Biospecimen Collection, Retinoid 9cUAB30, Therapeutic Conventional Surgery
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 7, 2026, 9:53 PM EDT
Recruiting No phase listed Observational

Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery

NCT04169542
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ, COVID-19 Infection, Hereditary Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
4
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 7, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 7, 2026, 9:53 PM EDT
Completed Not applicable Interventional Results available

Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer

NCT00694577
View directory record Official record
Conditions
Ductal Breast Cancer
Interventions
Partial Breast Irradiation using 32 Gy / 8 fractions, Partial Breast Irradiation using 36 Gy / 9 fractions, Partial Breast Irradiation using 40 Gy /10 fractions
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 7, 2026, 9:53 PM EDT
Recruiting Not applicable Interventional

Personalized Prone Immobilization for Accelerated Partial Breast Radiotherapy

NCT07711847
View directory record Official record
Conditions
Invasive Breast Cancer Early Stages, Ductal Carcinoma In Situ, DCIS
Interventions
VENUS SHELL™ immobilization device
Device
Lead sponsor
HeroSupport SA
Industry
Eligibility
40 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 7, 2026, 9:53 PM EDT
Completed Phase 1Phase 2 Interventional

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

NCT05900986
View directory record Official record
Conditions
Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
Interventions
LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg, LS301-IT 0.1 mg/kg
Drug
Lead sponsor
Integro Theranostics
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Weston, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 7, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Results available

Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

NCT00290732
View directory record Official record
Conditions
Breast Cancer
Interventions
Intraductal arm, Intravenous arm
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 7, 2026, 9:53 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

NCT00295893
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride, Trastuzumab, Carboplatin, Paclitaxel
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 7, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

NCT01082211
View directory record Official record
Conditions
Breast Cancer
Interventions
3D-Conformal External Beam
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
57
States / cities
Peoria, Arizona • Burbank, California • Aurora, Colorado + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 7, 2026, 9:53 PM EDT
Active, not recruiting Phase 3 Interventional

Breast Cancer WEight Loss Study (BWEL Study)

NCT02750826
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Synchronous Bilateral Breast Carcinoma
Interventions
Health Education Program, Weight Loss Intervention
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
3,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1464
States / cities
Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 921 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 7, 2026, 9:53 PM EDT
Completed No phase listed Observational

Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System

NCT06133647
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Invasive Lobular Breast Carcinoma
Interventions
managing Male Breast Cancer Patients at Methodist Health System
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
8 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 7, 2026, 9:53 PM EDT
Completed Not applicable Interventional Results available

Radiation Therapy in Treating Patients With Recurrent Breast Cancer

NCT00945061
View directory record Official record
Conditions
Breast Cancer
Interventions
intracavitary balloon brachytherapy, intraoperative radiation therapy
Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
3
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 7, 2026, 9:53 PM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 7, 2026, 9:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)

NCT02365714
View directory record Official record
Conditions
Breast Cancer, DCIS, Invasive Ductal Carcinoma
Interventions
CK Stereotactic Accelerated Partial Breast Irradiation
Radiation
Lead sponsor
Georgetown University
Other
Eligibility
50 Years to 99 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 7, 2026, 9:53 PM EDT
Recruiting No phase listed Observational

Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer

NCT06666439
View directory record Official record
Conditions
Metastatic Invasive Lobular Carcinoma (mILC)
Interventions
circulating tumor DNA (ctDNA)
Diagnostic Test
Lead sponsor
Julia Foldi
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 7, 2026, 9:53 PM EDT
Active, not recruiting Phase 2 Interventional

Metformin and Nightly Fasting in Women With Early Breast Cancer

NCT05023967
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Biospecimen Collection, Extended Release Metformin Hydrochloride, Monitoring, Nutritional Assessment, Short-Term Fasting
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 7, 2026, 9:53 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer

NCT00027534
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
TRICOM-CEA(6D)
Biological
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 7, 2026, 9:53 PM EDT